FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160298367> ?p ?o ?g. }

• W2160298367 endingPage "178" @default.
• W2160298367 startingPage "173" @default.
• W2160298367 abstract "Background. Platinum, antracyline, and fluoropyrimidine combination chemotherapy has been widely used as a first-line treatment for advanced gastric cancer (AGC). In the present study, we determined the efficacy and the safety of docetaxel and oral etoposide as second-line combination chemotherapy after failure of commonly used combination regimens in AGC. Methods. Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m 2 as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m 2 once daily on days 1—5, every 3 weeks until disease progression or unacceptable toxicities. Results. Between June 2006 and September 2008, 32 patients, of median age 60 years (range 32—77 years) were included in the study. Overall response rate was 9.4% and 31.3% of patients achieved a stable disease. Median progression-free survival was 3 months (95% CI, 2.5—3.5). Median overall survival was 6 months (95% CI, 3.8—8.2) with 16.9% 1-year survival rate. Grade 3—4 toxicities included neutropenia (28.8%), febrile neutropenia (18.8%), thrombocytopenia (3.1%), nausea and vomiting (15.6%), diarrhea (9.4%), and mucositis (6.2%). Conclusion. Docetaxel and oral etoposide combination was moderately effective and safe in appropriately selected AGC patients after failure of platinum- and fluoropyrimidine-based combination regimens. J Oncol Pharm Practice (2010) 16: 173—178." @default.
• W2160298367 created "2016-06-24" @default.
• W2160298367 creator A5001020870 @default.
• W2160298367 creator A5002622942 @default.
• W2160298367 creator A5005684031 @default.
• W2160298367 creator A5008382382 @default.
• W2160298367 creator A5020882531 @default.
• W2160298367 creator A5033726162 @default.
• W2160298367 creator A5033820961 @default.
• W2160298367 creator A5036133439 @default.
• W2160298367 creator A5045696675 @default.
• W2160298367 creator A5058387367 @default.
• W2160298367 creator A5070516783 @default.
• W2160298367 creator A5075330567 @default.
• W2160298367 creator A5077193503 @default.
• W2160298367 creator A5082587759 @default.
• W2160298367 date "2009-10-15" @default.
• W2160298367 modified "2023-10-17" @default.
• W2160298367 title "Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens" @default.
• W2160298367 cites W1955033393 @default.
• W2160298367 cites W1968198462 @default.
• W2160298367 cites W1972732503 @default.
• W2160298367 cites W1976651872 @default.
• W2160298367 cites W1981307221 @default.
• W2160298367 cites W1992408996 @default.
• W2160298367 cites W2012270736 @default.
• W2160298367 cites W2020830322 @default.
• W2160298367 cites W2042940383 @default.
• W2160298367 cites W2055317360 @default.
• W2160298367 cites W2103245073 @default.
• W2160298367 cites W2113229081 @default.
• W2160298367 cites W2122866527 @default.
• W2160298367 cites W2130522735 @default.
• W2160298367 cites W2139248078 @default.
• W2160298367 cites W2142269050 @default.
• W2160298367 cites W2145390243 @default.
• W2160298367 cites W2167112387 @default.
• W2160298367 cites W4293241248 @default.
• W2160298367 doi "https://doi.org/10.1177/1078155209347402" @default.
• W2160298367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19833685" @default.
• W2160298367 hasPublicationYear "2009" @default.
• W2160298367 type Work @default.
• W2160298367 sameAs 2160298367 @default.
• W2160298367 citedByCount "5" @default.
• W2160298367 countsByYear W21602983672012 @default.
• W2160298367 countsByYear W21602983672015 @default.
• W2160298367 countsByYear W21602983672023 @default.
• W2160298367 crossrefType "journal-article" @default.
• W2160298367 hasAuthorship W2160298367A5001020870 @default.
• W2160298367 hasAuthorship W2160298367A5002622942 @default.
• W2160298367 hasAuthorship W2160298367A5005684031 @default.
• W2160298367 hasAuthorship W2160298367A5008382382 @default.
• W2160298367 hasAuthorship W2160298367A5020882531 @default.
• W2160298367 hasAuthorship W2160298367A5033726162 @default.
• W2160298367 hasAuthorship W2160298367A5033820961 @default.
• W2160298367 hasAuthorship W2160298367A5036133439 @default.
• W2160298367 hasAuthorship W2160298367A5045696675 @default.
• W2160298367 hasAuthorship W2160298367A5058387367 @default.
• W2160298367 hasAuthorship W2160298367A5070516783 @default.
• W2160298367 hasAuthorship W2160298367A5075330567 @default.
• W2160298367 hasAuthorship W2160298367A5077193503 @default.
• W2160298367 hasAuthorship W2160298367A5082587759 @default.
• W2160298367 hasConcept C121608353 @default.
• W2160298367 hasConcept C126322002 @default.
• W2160298367 hasConcept C141071460 @default.
• W2160298367 hasConcept C143998085 @default.
• W2160298367 hasConcept C2776694085 @default.
• W2160298367 hasConcept C2777063308 @default.
• W2160298367 hasConcept C2778119113 @default.
• W2160298367 hasConcept C2778496288 @default.
• W2160298367 hasConcept C2778850193 @default.
• W2160298367 hasConcept C2780580376 @default.
• W2160298367 hasConcept C2780852908 @default.
• W2160298367 hasConcept C2781190966 @default.
• W2160298367 hasConcept C71924100 @default.
• W2160298367 hasConcept C90924648 @default.
• W2160298367 hasConceptScore W2160298367C121608353 @default.
• W2160298367 hasConceptScore W2160298367C126322002 @default.
• W2160298367 hasConceptScore W2160298367C141071460 @default.
• W2160298367 hasConceptScore W2160298367C143998085 @default.
• W2160298367 hasConceptScore W2160298367C2776694085 @default.
• W2160298367 hasConceptScore W2160298367C2777063308 @default.
• W2160298367 hasConceptScore W2160298367C2778119113 @default.
• W2160298367 hasConceptScore W2160298367C2778496288 @default.
• W2160298367 hasConceptScore W2160298367C2778850193 @default.
• W2160298367 hasConceptScore W2160298367C2780580376 @default.
• W2160298367 hasConceptScore W2160298367C2780852908 @default.
• W2160298367 hasConceptScore W2160298367C2781190966 @default.
• W2160298367 hasConceptScore W2160298367C71924100 @default.
• W2160298367 hasConceptScore W2160298367C90924648 @default.
• W2160298367 hasIssue "3" @default.
• W2160298367 hasLocation W21602983671 @default.
• W2160298367 hasLocation W21602983672 @default.
• W2160298367 hasOpenAccess W2160298367 @default.
• W2160298367 hasPrimaryLocation W21602983671 @default.
• W2160298367 hasRelatedWork W2003291927 @default.
• W2160298367 hasRelatedWork W2051535219 @default.
• W2160298367 hasRelatedWork W2084246274 @default.

• next